Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment — CDGP  

Constitutional Delay of Growth and Puberty Clinical Trial

Official title: Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment

Status Completed

Clinical Trial Summary

Boys with constitutional delay of growth and puberty (CDGP) should be offered evidence-based effective and safe treatment option. This study compares the effects of low-dose testosterone and aromatase inhibitor letrozole on pubertal progression. The hypothesis is that, in boys CDGP showing earliest signs of puberty, peroral letrozole (2.5 mg/d for 6 mo) induces faster biochemical and clinical progression of puberty as compared to low-dose intramuscular testosterone Rx (~1mg/kg/mo for 6 mo). In addition, 10 or more boys who select watchful waiting instead of medication will provide background data on the natural progression of CDGP, and their data will not be used in primary statistical comparisons.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Constitutional Delay of Growth and Puberty

• NCT number: NCT01797718
• Study type: Interventional
• Source: Helsinki University Central Hospital
• Status: Completed
• Phase: Phase 2/Phase 3
• Start date: October 2013
• Completion date: February 5, 2018